An interventional study of Transcranial magnetic stimulation targeting occipital visual cortex and Sham stimulation in Retinal Degeneration and Vision Impairment and Blindness, sponsored by Shanghai High Myopia Study Group. Not yet recruiting at 4 sites in China. Open to participants aged 45 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-02-23.
Sponsored by Shanghai High Myopia Study Group · Not applicable, Interventional, and Treatment
The goal of this clinical trial is to learn if transcranial magnetic stimulation (TMS) works to restore vision in adults with severe retinal degeneration. It will also learn about the safety of TMS treatment. The main questions it aims to answer are:
Participants will:
UndergoTMS treatment to a sham stimulation for consecutive 5 days Visit the clinic at 5 days, 4 weeks, 3 months, 6 months, 12 months after start of the treatment for checkups and tests
132 studies on the registry are indexed under Retinal Degeneration; 23 are open to participants now.
This study's planned enrollment of 136 is above the median of 40 across 98 interventional studies indexed under Retinal Degeneration.
Browse Retinal Degeneration studies →Shanghai High Myopia Study Group is the lead sponsor of 4 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The TMS group will receive theta burst stimulation targeting bilateral occipital visual cortex, with five consecutive daily sessions.
Procedure: Transcranial magnetic stimulation targeting occipital visual cortex
The control group will undergo identical procedures using a sham coil without effective magnetic field output.
Procedure: Sham stimulation
Transcranial magnetic stimulation targeting occipital visual cortex
identical procedure using a sham coil without effective magnetic field output
Best-corrected visual acuity (BCVA) change
the change of best-corrected visual acuity (BCVA, measured by internationally standard EDTRS chart) between 3 months after the end of treatment and baseline
Time frame: Baseline and 3 months
Best-corrected visual acuity (BCVA) change
the change of BCVA (EDTRS) between 12 months after treatment and baseline
Time frame: Baseline and 12 months
Visual field progression
Visual field progression measured as mean defect (MD) from baseline to 3 months post-treatment
Time frame: Baseline and 3 months
Contrast sensitivity function change
Change in contrast sensitivity function from baseline to 3 months post-treatment
Time frame: baseline and 3 months
Retinal structural alteration by fundus optical coherence tomography
Retinal structural alteration measured by fundus optical coherence tomography from baseline to 3 months after treatment
Time frame: Baseline and 3 months
Change in scores of subjective questionnaire VFQ-25
Change in scores of subjective vision-related quality of life (VFQ-25) questionnaire from baseline to 3 months after treatment
Time frame: baseline and 3 months
Change in scores of subjective questionnaire health-related quality of life (HRQL)
Change in scores of subjective health-related quality of life (HRQL) questionnaire from baseline to 3 months after treatment
Time frame: baseline and 3 months
number of adverse events
the number of adverse events during 12-month follow-up
Time frame: baseline to 12 months
the number of additional surgical interventions during 12-month follow-up
Time frame: baseline and 12 months
Plan to share: Yes — De-identified raw study data eligible for secondary analysis will be made available, including baseline characteristics, outcome measures, adverse events (AEs) and group allocation information.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Beginning 1 year after publication and ending 3 years after the publication of results
Access criteria: Investigators who need to use the data for secondary analysis must provide a proposal that describes planned analyses and sign data sharing agreement after the principal investigators approve the proposals.
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai High Myopia Study Group